Huntington disease
Summary
Definition
History and exam
Key diagnostic factors
- positive family history of Huntington disease
- known expansion of the CAG repeat length at the N-terminal end of the huntingtin gene
- impaired work or school performance
- personality change
- irritability and impulsivity
- chorea
- twitching or restlessness
- loss of coordination
- deficit in fine motor coordination
- slowed rapid (saccadic) eye movements
- motor impersistence
- impaired tandem walking
Other diagnostic factors
- concentration impairment/task anxiety or apathy
- cognitive decline relative to spouse/siblings
- changes in personal habits/hygiene
- disinhibition or unusually anxious behavior
- depression, obsessions, and compulsions
Risk factors
- expansion of the CAG repeat length at the N-terminal end of the huntingtin gene
- other genetic factors
- family history
Diagnostic investigations
1st investigations to order
- no initial tests
Investigations to consider
- CAG repeat testing
- MRI or CT scan
Treatment algorithm
all patients
Contributors
Authors
Mitsuko Nakajima, MD
Clinical Research Fellow
Huntington's Disease Centre
Queen Square
Institute of Neurology
Department of Neurodegenerative Disease
Russell Square House
London
UK
Disclosures
MN declares no competing interests.
Acknowledgements
Dr Mitsuko Nakajima would like to gratefully acknowledge Dr Peter McColgan, Dr Sarah Tabrizi, Dr David Craufurd, Dr Marianne Novak, and Dr Francis Walker, previous contributors to this topic.
Disclosures
FW declared that he had no competing interests. MN is an author of a reference cited in this topic. DC has received fees for advisory board membership from Hoffmann-La Roche Ltd. SJT has received grant funding for her research from CHDI Foundation, the BBSRC, Dementia and Neurodegenerative Disease Network UK, European Huntington’s Disease Network, Huntington’s Disease Association of the UK, the Medical Research Council UK, Takeda Pharmaceuticals, the UCL/UCLH Biomedical Research Center, and the Wellcome Trust. SJT has been on advisory boards or had consultancies with F. Hoffmann-La Roche Ltd, Ixico Technologies, Shire Human Genetic Therapies, Takeda Pharmaceuticals International, and TEVA Pharmaceuticals; all honoraria for these consultancies and advisory boards were paid to UCL. Through the offices of UCL Consultants Ltd, a wholly owned subsidiary of UCL, SJT has undertaken consultancy services for F. Hoffmann-La Roche Ltd and GSK. ST is also an author of references cited in this topic PM declared that he had no competing interests.
Peer reviewers
Adrian Priesol, MD, FRCPC
Instructor
Massachusetts Eye and Ear Infirmary
Harvard Medical School
Boston
MA
Disclosures
AP declares that he has no competing interests.
Tiago Mestre, MD, MSc
Resident Neurology
Neurological Clinical Research Unit
Institute of Molecular Medicine
Lisbon
Portugal
Disclosures
TM declares that he has no competing interests.
Differentials
- Tardive dyskinesia
- Dentatorubro-pallidoluysian atrophy (DRPLA)
- Neuroacanthocytosis
More DifferentialsGuidelines
- Clinical guidance in neuropalliative care: an AAN position statement
- Clinical recommendations to guide physical therapy practice for Huntington disease
More GuidelinesPatient leaflets
Depression in adults
Huntington’s disease
More Patient leaflets
Log in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer